All In Biotech

Drug Trial Radar · NCT07015905

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jun 25, 2025

Primary completion

Feb 20, 2027

Study completion May 12, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

  • Venous Thromboembolism (VTE)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • ApixabanDrug

    Administered per the protocol

  • EnoxaparinDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]Time frame: Through day 12 visit, approximately 14 days

Locations

47 sites in 8 countries. Site status is shown where the registry gives one.

  • Shoals Medical Trials, Inc.

    Sheffield, Alabama · Recruiting

  • CARI Clinical Trials

    Riverside, California · Recruiting

  • Denver Metro Orthopedics, P.C. Englewood Location

    Englewood, Colorado · Recruiting

  • Delray Physician Care Center

    Delray Beach, Florida · Recruiting

  • Bioresearch Partner

    Miami, Florida · Recruiting

  • Sacred Heart Health System Inc

    Pensacola, Florida · Recruiting

  • Gulfcoast Research Institute

    Sarasota, Florida · Recruiting

  • Phoenix Clinical Research

    Tamarac, Florida · Recruiting

  • Sinai Hospital of Baltimore, Inc.

    Baltimore, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Curalta Clinical Trials

    Westwood, New Jersey · Recruiting

  • Duke University Health System (Duke Health), Duke University Hospital

    Durham, North Carolina · Recruiting

  • Keystone Clinical Studies LLC, dba Flourish Research

    Plymouth Meeting, Pennsylvania · Withdrawn

  • HD Research - First Surgical Hospital

    Bellaire, Texas · Recruiting

  • University of Texas (UT); Southwestern Medical Center

    Dallas, Texas · Recruiting

  • NextStage Clinical Research, All American Orthopedics and Sports Medicine

    Houston, Texas · Completed

  • Futuro Clinical Trials

    McAllen, Texas · Recruiting

  • Flourish Research - San Antonio (Formerly Clinical Trials of Texas)

    San Antonio, Texas · Recruiting

  • DRx Clinical Research, LLC; South Texas Bone and Joint Institute

    San Antonio, Texas · Recruiting

  • DRx Clinical Research, LLC

    St. George, Utah · Recruiting

  • Multi-profile Hospital for Active Treatment Hearth and Brain EAD

    Pleven, Bulgaria · Recruiting

  • Multiprofile Hospital for Active Treatment; Sveta Sofia EOOD (MBAL Sveta Sofia),

    Sofia, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment "Prof. Dr. Stoyan Kirkovich"

    Stara Zagora, Bulgaria · Withdrawn

  • Semmelweis University

    Budapest, Hungary · Recruiting

  • Szegedi Tudomanyegyetem; Albert Szent-Gyorgyi Clinical Center

    Szeged, Csongrad-Csanad, Hungary · Recruiting

  • Gyor-Moson-Sopron Varmegyei Egyetemi Oktato Korhaz

    Győr, Győr-Moson-Sopron, Hungary · Recruiting

  • University of Debrecen

    Debrecen, Hajdú-Bihar, Hungary · Recruiting

  • Saga University Hospital

    Saga, Japan · Recruiting

  • Kansai Rosai Hospital

    Amagasaki-shi, Hyōgo, Japan · Recruiting

  • Yuuai Medical Center

    Tomigusuku, Okinawa, Japan · Recruiting

  • National Hospital Organization Osaka Minami Medical Center

    Kawachi-Nagano, Osaka, Japan · Recruiting

  • Osaka Saiseikai Nakatsu Hospital

    Kita-Ku, Osaka, Japan · Recruiting

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Liepajas regionala slimnica; SIA

    Liepāja, Latvia · Recruiting

  • Rigas 2 slimnica, SIA

    Riga, Latvia · Recruiting

  • Hospital of Traumatology and Orthopaedics

    Riga, Latvia · Recruiting

  • ORTO Klinika

    Riga, Latvia · Recruiting

  • Vidzemes slimnica

    Valmiera, Latvia · Recruiting

  • Lietuvos sveikatos mokslu universiteto Kauno ligonine

    Kaunas, Lithuania · Recruiting

  • Lietuvos sveikatos mokslu universiteto ligonine Kauno klinik

    Kaunas, Lithuania · Recruiting

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.